Drugs / GB10
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07406438 | Feb 2026 → Apr 2027 expected | wet macular degeneration | Shenzhen Kexing Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07406438 ↗ |
| Route | Intravitreal | “GB10 intravitreal (IVT) injection” NCT07406438 ↗ |